- Home
- RMBI vs BMEA Comparison
RMBI vs BMEA Comparison
Compare RMBI & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMBI
- BMEA
- Stock Information
- Founded
- RMBI 1887
- BMEA 2017
- Country
- RMBI United States
- BMEA United States
- Employees
- RMBI N/A
- BMEA N/A
- Industry
- RMBI Major Banks
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- RMBI Finance
- BMEA Health Care
- Exchange
- RMBI Nasdaq
- BMEA Nasdaq
- Market Cap
- RMBI 128.3M
- BMEA 125.4M
- IPO Year
- RMBI 2019
- BMEA 2021
- Fundamental
- Price
- RMBI $12.75
- BMEA $2.00
- Analyst Decision
- RMBI
- BMEA Buy
- Analyst Count
- RMBI 0
- BMEA 13
- Target Price
- RMBI N/A
- BMEA $27.92
- AVG Volume (30 Days)
- RMBI 28.9K
- BMEA 636.9K
- Earning Date
- RMBI 04-24-2025
- BMEA 05-01-2025
- Dividend Yield
- RMBI 4.69%
- BMEA N/A
- EPS Growth
- RMBI 1.10
- BMEA N/A
- EPS
- RMBI 0.92
- BMEA N/A
- Revenue
- RMBI $42,915,048.00
- BMEA N/A
- Revenue This Year
- RMBI N/A
- BMEA $191.34
- Revenue Next Year
- RMBI N/A
- BMEA N/A
- P/E Ratio
- RMBI $13.91
- BMEA N/A
- Revenue Growth
- RMBI 2.81
- BMEA N/A
- 52 Week Low
- RMBI $10.15
- BMEA $1.94
- 52 Week High
- RMBI $15.15
- BMEA $14.43
- Technical
- Relative Strength Index (RSI)
- RMBI 48.63
- BMEA 28.47
- Support Level
- RMBI $12.60
- BMEA $2.27
- Resistance Level
- RMBI $13.40
- BMEA $3.08
- Average True Range (ATR)
- RMBI 0.38
- BMEA 0.23
- MACD
- RMBI 0.08
- BMEA 0.00
- Stochastic Oscillator
- RMBI 52.90
- BMEA 2.95
About RMBI Richmond Mutual Bancorporation Inc.
Richmond Mutual Bancorp Inc is a United States-based banking company. Its principal business consists of attracting deposits from the general public & brokered deposits and investing those funds predominantly in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one-to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.